pentoxifylline has been researched along with Cachexia in 14 studies
Cachexia: General ill health, malnutrition, and weight loss, usually associated with chronic disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Based on evidence that suggests pentoxifylline can inhibit tumor necrosis factor, we set out to evaluate the activity and toxicity of this drug in patients with cancer-associated anorexia and/or cachexia." | 9.08 | Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. ( Chong, SF; Ghosh, C; Goldberg, RM; Hestorff, RD; Krook, JE; Loprinzi, CL; Mailliard, JA; O'Fallon, JR; Reuter, NF; Shanahan, TG, 1995) |
| "Cardiac cachexia was rapidly induced with monocrotaline in Sprague-Dawley rats." | 5.35 | Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia. ( Booth, FW; Lees, SJ; Steffen, BT, 2008) |
| "Pentoxifylline (PTX) is a very inexpensive xanthine derivative, which is widely used in humans as a haemorheological agent, and inhibits tumor necrosis factor transcription." | 5.30 | Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats. ( Attaix, D; Combaret, L; Rallière, C; Taillandier, D; Tanaka, K, 1999) |
| "Based on evidence that suggests pentoxifylline can inhibit tumor necrosis factor, we set out to evaluate the activity and toxicity of this drug in patients with cancer-associated anorexia and/or cachexia." | 5.08 | Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. ( Chong, SF; Ghosh, C; Goldberg, RM; Hestorff, RD; Krook, JE; Loprinzi, CL; Mailliard, JA; O'Fallon, JR; Reuter, NF; Shanahan, TG, 1995) |
| "Tumor necrosis factor-alpha (TNF-alpha) is thought to induce cachexia in subjects infected with human immunodeficiency virus (HIV), and it has been suggested that HIV-seropositive patients would benefit from treatment with pentoxifylline, a known suppressor of TNF-alpha production." | 5.08 | Pentoxifylline therapy in HIV seropositive subjects with elevated TNF. ( Bruunsgaard, H; Kappel, M; Kruse, A; Orholm, M; Pedersen, BK; Rieneck, K; Skinhøj, P; Ullum, H, 1995) |
| "Pentoxifylline (PTX) is a drug that has been shown to have multiple beneficial effects in cancer patients through its anti-inflammatory properties." | 3.01 | Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I). ( Baider, L; Barak, V; Meirovitz, A; Peretz, T; Stephanos, S, 2021) |
| "Studies have recruited heterogeneous cancer patient populations in late disease stages, and many had issues with accrual and attrition." | 2.61 | Anti-cytokines in the treatment of cancer cachexia. ( Prado, BL; Qian, Y, 2019) |
| "Cancer anorexia and cachexia are two distinct syndromes which may have synergistic effects in a patient." | 2.41 | [Tumour anorexia--tumour cachexia in case of gastrointestinal tumours: standards and visions]. ( Gastell, S; Lochs, H; Ockenga, J; Pirlich, M, 2002) |
| "Cardiac cachexia was rapidly induced with monocrotaline in Sprague-Dawley rats." | 1.35 | Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia. ( Booth, FW; Lees, SJ; Steffen, BT, 2008) |
| "Cancer cachexia is characterized by skeletal muscle wasting that is mainly supported by hypercatabolism." | 1.33 | IGF-1 is downregulated in experimental cancer cachexia. ( Argilés, JM; Baccino, FM; Bonelli, G; Bonetto, A; Bossola, M; Busquets, S; Costelli, P; Doglietto, GB; Lopez-Soriano, FJ; Muscaritoli, M; Penna, F; Reffo, P; Rossi Fanelli, F, 2006) |
| "Pentoxifylline (PTX) is a very inexpensive xanthine derivative, which is widely used in humans as a haemorheological agent, and inhibits tumor necrosis factor transcription." | 1.30 | Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats. ( Attaix, D; Combaret, L; Rallière, C; Taillandier, D; Tanaka, K, 1999) |
| "Pentoxifylline did not suppress TNF RNA to subnormal levels in all five patients with initially normal TNF RNA levels." | 1.29 | Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study. ( Allen-Ryan, J; Dezube, BJ; Fridovich-Keil, JL; Pardee, AB; Sherman, ML, 1993) |
| "Severe weight loss is a common manifestation of advanced infection with the human immunodeficiency virus." | 1.29 | Use of pentoxifylline therapy for patients with AIDS-related wasting: pilot study. ( Landman, D; Sarai, A; Sathe, SS, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (42.86) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Meirovitz, A | 1 |
| Baider, L | 1 |
| Peretz, T | 1 |
| Stephanos, S | 1 |
| Barak, V | 1 |
| Prado, BL | 1 |
| Qian, Y | 1 |
| Kalantar-Zadeh, K | 1 |
| Anker, SD | 1 |
| Horwich, TB | 1 |
| Fonarow, GC | 1 |
| Steffen, BT | 1 |
| Lees, SJ | 1 |
| Booth, FW | 1 |
| Ockenga, J | 1 |
| Pirlich, M | 1 |
| Gastell, S | 1 |
| Lochs, H | 1 |
| Argilés, JM | 3 |
| Busquets, S | 3 |
| López-Soriano, FJ | 2 |
| Costelli, P | 2 |
| Muscaritoli, M | 1 |
| Bossola, M | 1 |
| Penna, F | 2 |
| Reffo, P | 2 |
| Bonetto, A | 1 |
| Bonelli, G | 2 |
| Doglietto, GB | 1 |
| Baccino, FM | 2 |
| Rossi Fanelli, F | 1 |
| Almendro, V | 1 |
| Figueras, MT | 1 |
| Aragno, M | 1 |
| Mastrocola, R | 1 |
| Boccuzzi, G | 1 |
| Lopez Soriano, FJ | 1 |
| Goldberg, RM | 1 |
| Loprinzi, CL | 1 |
| Mailliard, JA | 1 |
| O'Fallon, JR | 1 |
| Krook, JE | 1 |
| Ghosh, C | 1 |
| Hestorff, RD | 1 |
| Chong, SF | 1 |
| Reuter, NF | 1 |
| Shanahan, TG | 1 |
| Dezube, BJ | 1 |
| Sherman, ML | 1 |
| Fridovich-Keil, JL | 1 |
| Allen-Ryan, J | 1 |
| Pardee, AB | 1 |
| Landman, D | 1 |
| Sarai, A | 1 |
| Sathe, SS | 1 |
| Kruse, A | 1 |
| Rieneck, K | 1 |
| Kappel, M | 1 |
| Orholm, M | 1 |
| Bruunsgaard, H | 1 |
| Ullum, H | 1 |
| Skinhøj, P | 1 |
| Pedersen, BK | 1 |
| Haslett, PA | 1 |
| Combaret, L | 1 |
| Rallière, C | 1 |
| Taillandier, D | 1 |
| Tanaka, K | 1 |
| Attaix, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer[NCT06115174] | Phase 4 | 44 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | ||
| Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Patients With Anorexia Associated With Advanced Lung Cancer: Randomized Double Blind Clinical Trial[NCT02802540] | Phase 2/Phase 3 | 78 participants (Anticipated) | Interventional | 2014-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for pentoxifylline and Cachexia
| Article | Year |
|---|---|
Anti-cytokines in the treatment of cancer cachexia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cachexia; Cytokines; Etanercept; Forecast | 2019 |
Nutritional and anti-inflammatory interventions in chronic heart failure.
Topics: Amino Acids; Anorexia; Antioxidants; Appetite Stimulants; Cachexia; Comorbidity; Dietary Supplements | 2008 |
[Tumour anorexia--tumour cachexia in case of gastrointestinal tumours: standards and visions].
Topics: Adrenal Cortex Hormones; Algorithms; Anorexia; Body Weight; Cachexia; Cyclooxygenase Inhibitors; Die | 2002 |
The pivotal role of cytokines in muscle wasting during cancer.
Topics: Animals; Anorexia; Antibodies; Cachexia; Cytokines; Humans; Models, Biological; Muscle, Skeletal; Mu | 2005 |
Anticytokine approaches to the treatment of anorexia and cachexia.
Topics: Anorexia; Cachexia; Humans; Immunosuppressive Agents; Interleukin-1; Interleukin-6; Pentoxifylline; | 1998 |
3 trials available for pentoxifylline and Cachexia
| Article | Year |
|---|---|
Effect of pentoxifylline on colon cancer patients treated with chemotherapy (Part I).
Topics: Aged; Antineoplastic Agents; Cachexia; Colonic Neoplasms; Disease Progression; Female; Fluorouracil; | 2021 |
Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial.
Topics: Aged; Anorexia; Appetite; Body Weight; Cachexia; Double-Blind Method; Female; Humans; Male; Middle A | 1995 |
Pentoxifylline therapy in HIV seropositive subjects with elevated TNF.
Topics: Adolescent; Adult; Aged; Cachexia; Cross-Over Studies; Female; Flow Cytometry; HIV Seropositivity; H | 1995 |
6 other studies available for pentoxifylline and Cachexia
| Article | Year |
|---|---|
Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia.
Topics: Animals; Anorexia; Blotting, Western; Body Weight; Cachexia; Eating; Enzyme-Linked Immunosorbent Ass | 2008 |
IGF-1 is downregulated in experimental cancer cachexia.
Topics: Adrenergic beta-Agonists; Animals; Cachexia; Down-Regulation; Enzyme Inhibitors; Ethanolamines; Form | 2006 |
Modulations of the calcineurin/NF-AT pathway in skeletal muscle atrophy.
Topics: Animals; Blotting, Western; Cachexia; Calcineurin; Carcinoma, Hepatocellular; DNA; DNA Primers; Elec | 2007 |
Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study.
Topics: Adult; Cachexia; Humans; Neoplasms; Pentoxifylline; Pilot Projects; RNA; Tumor Necrosis Factor-alpha | 1993 |
Use of pentoxifylline therapy for patients with AIDS-related wasting: pilot study.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cachexia; Humans; Male; Middle Aged; Pentoxifylline; Pilo | 1994 |
Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats.
Topics: Adenosine Triphosphatases; Animals; Cachexia; Cysteine Endopeptidases; Enzyme Activation; Multienzym | 1999 |